Telix Pharmaceuticals Limited (TLX) — Stock Price, Chart & Analysis
Telix Pharmaceuticals Limited (TLX) is a Healthcare stock currently trading at $11.95, up 5.66% on the day. It carries a market capitalization of $4.06B and a trailing P/E ratio of 119.50. Over the past 52 weeks, TLX has traded between $6.28 and $13.11. Telix Pharmaceuticals Limited does not currently pay a regular dividend. View the live TLX chart, technical opinion, analyst ratings, fundamentals and latest news below.
Telix Pharmaceuticals Limited (TLX) key data
| Price | $11.95 |
| Change (today) | +5.66% |
| Previous close | $11.31 |
| Market cap | $4.06B |
| P/E ratio (TTM) | 119.50 |
| EPS (TTM) | $0.10 |
| 52-week high | $13.11 |
| 52-week low | $6.28 |
| Beta | 0.60 |
| Avg. volume | 205.5K |
| Sector | Healthcare |
| Industry | Biotechnology |
Frequently asked questions about Telix Pharmaceuticals Limited (TLX)
How much does one share of Telix Pharmaceuticals Limited cost?
As of the latest update, one share of Telix Pharmaceuticals Limited (TLX) trades at $11.95 (+5.66% today).
What is Telix Pharmaceuticals Limited's market cap?
Telix Pharmaceuticals Limited has a market capitalization of approximately $4.06B.
What is Telix Pharmaceuticals Limited's P/E ratio?
Telix Pharmaceuticals Limited has a trailing price-to-earnings (P/E) ratio of 119.50.
What is Telix Pharmaceuticals Limited's earnings per share (EPS)?
Telix Pharmaceuticals Limited's trailing twelve-month EPS is $0.10.
Does Telix Pharmaceuticals Limited pay a dividend?
Telix Pharmaceuticals Limited does not currently pay a regular dividend.
What is Telix Pharmaceuticals Limited's 52-week trading range?
Over the past year, TLX has traded between $6.28 and $13.11.
What is the analyst price target for Telix Pharmaceuticals Limited?
The mean analyst price target for Telix Pharmaceuticals Limited is $19.85. This is informational only and not investment advice.
Latest Telix Pharmaceuticals Limited (TLX) news
- Telix (TLX) to Buy Germany’s ITM for up to $2.35 Billion to Lock in its Cancer Isotope SupplyNews · Sep 22, 2026
- Telix Pharmaceuticals (ASX:TLX) Lands $2.35 Billion Deal To Reshape Radiopharmaceutical ReachNews · Sep 22, 2026
- Telix Beefs Up Radioisotopes Supply With $2.35 Billion Deal; Shares CrashNews · Sep 21, 2026
- Telix to Buy Germany's ITM Isotope in Deal Worth Up to $2.35 BillionNews · Sep 21, 2026
- Telix to acquire ITM in deal worth up to $2.35bnNews · Sep 21, 2026
- FDA Approves Telix’s Brain Cancer Imaging Drug PixclaraNews · Sep 14, 2026
Headlines via Yahoo Finance and publishers — click through to read each story at its source.
Loading the live TLX dashboard…